JADE101
Asset
Blocks APRIL signaling to reduce antibody production, including pathogenic IgA.
- Stage
- Phase 3
- Modality
- Antibody
- Target
- TNFSF13
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1IgA nephropathy
Phase 3, Recruiting, NCT07902817, clinicaltrials.gov, Nov 3, 2026
In the full profile
- Target and mechanism1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Competitors8
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.